Sign in or register today for access to this and other blogs and discussions.
Arthur Moss answers CardioExchange's questions about his research group's MADIT-RIT trial, which found a significant survival benefit from programming implantable cardioverter-defibrillators to minimize inappropriate therapy. Ask your own questions or share your perspective here.
CardioExchange is an online community hosted by the New England Journal of Medicine and Journal Watch and dedicated to improving cardiac patient care. Membership is free for medical professionals.